|
|
 |
|
Viewing report
|
|
|
|
Global Schizophrenia Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
Commercial Insights, May 2011, Pages: 114
The global schizophrenia therapeutics market was valued at $6.7 billion in 2010, and is expected to reach $7.3 billion by 2018, increasing at a CAGR of 7.5% between 2010 and 2018. Schizophrenia markets in Europe and Japan are expected to witness stronger growth compared to the US. The patent expiration of many leading Schizophrenia therapies has also resulted in their mass genericization.
However, factors such as rising schizophrenia prevalence in all seven top pharmaceutical markets along with an increasing schizophrenia diagnosis rate and the schizophrenia treated population rate, will offset the declining market. Also, the report foresees the rapid uptake of Invega Sustenna and some of the high potential pipeline molecules, as significant market events contributing to higher sales revenues.
Research Scope:
- Geographies Covered: The US, Germany, France, UK, Spain, Italy, and Japan
- Forecast Period: 8 Years (2010 to 2018)
Market Analysis:
- Schizophrenia therapeutics market size and forecast by geography
- Insights into market events that impact the schizophrenia therapeutics market by geography
- Leading therapies by geography
Competitive Landscape Analysis:
- Market share insights of leading brands in the global schizophrenia therapeutics market
- Future market share analysis of the global schizophrenia therapeutics market
- Profiles of leading brands by annual therapy cost and their market shares
Patient Flow Analysis:
- Patient flow study with diagnosis rate and treated population rate by geography
- Analysis and forecasts of schizophrenia prevalence population by geography
- Analysis and forecasts of schizophrenia diagnosed population by geography
- Analysis and forecasts of schizophrenia treated population by geography
Unmet Need:
- Unmet need analysis of the global schizophrenia therapeutics market
Pipeline Analysis:
- Analysis of schizophrenia pipeline molecules by phase of development
- Detailed clinical profiles of high potential phase 3 molecules
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
